AGI's echocardiography and pressure-volume loop platforms enable sponsors to characterize cardiac performance across systolic, diastolic, and vascular endpoints with exceptional resolution. These studies capture detailed hemodynamic data including ejection fraction, cardiac output, ventricular compliance, and vascular resistance, providing mechanistic insight into how novel therapeutics influence cardiac function under clinically relevant conditions. Using catheter-based PV loop analysis alongside Doppler echocardiography, we deliver continuous data streams that map real-time cardiac physiology during dosing, stress testing, and recovery phases. This integration enables early detection of subtle drug-induced changes that may otherwise remain undetected, reducing downstream safety risks.

 

Complementary assays in serum biomarkers, histopathology, and molecular profiling validate functional findings at the tissue level, ensuring that observed changes are both quantifiable and mechanistically supported. All data are generated under GLP standards and formatted for regulatory submission, aligning with FDA and EMA expectations for cardiovascular safety evaluation. By combining high-precision imaging with advanced analytics and translational rigor, our cardiac platforms provide the reproducible datasets needed to de-risk therapeutic programs and guide successful clinical development.